Stockreport

Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress

Zentalis Pharmaceuticals, Inc. - common stock  (ZNTL) 
PDF Azenosertib clinical development plan on track with multiple data readouts in gynecological and other cancer types anticipated in the second half of 2024 and into 2025 [Read more]